What does a high Lp(a) mean? An inherited risk, tested once

A high Lp(a) means you carry more of one specific particle, and the research treats that particle as a cause of heart disease rather than a bystander. Lipoprotein(a), written Lp(a), is a particle much like LDL cholesterol with an extra protein clamped onto it.

A 2022 American Heart Association statement and a 2022 European Atherosclerosis Society consensus statement both concluded that high levels independently and causally raise the risk of atherosclerotic cardiovascular disease, meaning arteries narrowed by fatty plaque, and of aortic stenosis, a stiffening of the main valve out of the heart [2] [14].

The longest look at what the number predicts followed 27,748 American women, typically in their fifties when they joined, for about 28 years, and recorded 3,707 major cardiovascular events, roughly 13 events for every 100 women in the study [15]. Set against women whose Lp(a) was below 10 mg/dL (milligrams per decilitre, the unit laboratories use for the concentration), those above 120 mg/dL were:

• about 80% more likely to develop coronary heart disease, meaning disease of the arteries that feed the heart
• about 63% more likely to die of a cardiovascular cause
• about 54% more likely to have a major cardiovascular event of any kind
• about 41% more likely to have an ischaemic stroke, a stroke caused by a blocked vessel, though that last comparison was too uncertain to rely on [15]

There is no clean cut-off. A 2010 European review found the relationship climbs continuously, with no threshold and no dependence on LDL levels [5], and across the general population Lp(a) runs from under 1 mg/dL to over 1,000 [13]. The number most often used as a flag is 50 mg/dL, which an estimated 20% to 25% of people worldwide are above [8]. A 2023 review puts the point where risk starts rising lower, at about 30 mg/dL [13], and the 30-year study in women agrees: above 30 mg/dL, a level three-quarters of them were below, predicted extra heart events, while the stroke and death signals only showed up above 120 [15].

A normal LDL result does not rule it out. The European panel found high Lp(a) still carried risk even at very low LDL cholesterol [14], and the American Heart Association statement found the same where both LDL and apoB had been brought down effectively, apoB being apolipoprotein B, the protein that rides one per particle on everything carrying cholesterol into artery walls [2]. It does not predict everything, though. Genetic studies have not tied high Lp(a) to venous thromboembolism, clots forming in the veins rather than the arteries, and the European panel reached the same conclusion [3] [14]. For narrowed leg arteries and for plaque in the neck arteries, the evidence is described as less conclusive than the coronary evidence [13].

Guidance on testing has converged on doing it once. A 2024 Lancet review advises people at higher cardiovascular risk to have Lp(a) measured once in their lifetime [1], and the 2022 European panel recommends testing at least once in every adult, plus testing close relatives where there is inherited high cholesterol, or a family or personal history of early heart disease or very high Lp(a) [14]. It needs no fasting [4].

No approved drug lowers Lp(a). Statins, fibrates and ezetimibe, the standard cholesterol-lowering drugs, move it very little [7] [8]. Injectable PCSK9 inhibitors, a newer cholesterol-lowering class, bring it down by about 25% to 30% [13], and filtering it out of the blood, a procedure called apheresis, works but is impractical as routine care [8].

At least five drugs in development cut Lp(a) by 65% to 98%, and as of that 2024 review three had reached large trials measuring actual heart events [1]. Those trials are what will settle whether lowering the number lowers the risk [8] [11]. All of it is prescription territory, decided with a doctor.

Lp(a) is an LDL-like particle with a second protein, apolipoprotein(a), locked onto it by a single chemical bridge [7] [13]. That extra protein is where the trouble starts. It closely resembles plasminogen, one of the proteins the body uses to dissolve clots, but it has none of plasminogen's clot-dissolving activity [5].

The particle does damage along several routes at once. It is the main carrier of oxidised phospholipids, damaged fat molecules that inflame the artery wall, and through them it drives plaque formation, inflammation, calcium deposits and clotting [7] [8] [14]. In the aortic valve, that calcium turns up both as microscopic specks and as deposits large enough to see [14]. Each Lp(a) particle also carries one apoB, so it delivers cholesterol into the artery wall much as LDL does [2].

Why the level barely budges comes down to gene structure. Lp(a) is built from the LPA gene, which contains a repeated segment called kringle IV-2 present in a variable number of copies, producing more than 40 different protein sizes [4]. Because both inherited copies of the gene are expressed, somewhere between 70% and more than 90% of the difference between people is genetic, and an individual's level stays roughly flat for life [2] [4] [10].

It is not completely fixed. The LPA gene carries a docking site for interleukin-6, a signal the body releases during inflammation, so an inflammatory illness can push Lp(a) up temporarily, and menopause, diet and kidney function can shift it as well [4]. Post-menopausal women average about 17% higher than men [1].

The hardest numbers here come from one narrow population. The 30-year study enrolled 27,748 female American health professionals, typically in their fifties, so it says nothing directly about men, about younger adults, or about people less engaged with their own health than that group, and the genetic half of it was restricted to women of European ancestry [15]. Its ischaemic stroke result above 120 mg/dL was too uncertain to rely on, and only firmed up when the comparison was narrowed to the top 1% against the bottom half [15].

Most of the rest of this evidence is review and consensus rather than trial. Those reviews summarise large cohort and genetic studies, but no completed trial has yet shown that lowering Lp(a) lowers heart events, which is precisely what the phase 3 trials still running, the last stage before a drug can be approved, are built to test [8] [11] [14].

Two practical problems sit underneath every figure above:

• Lp(a) tests are not standardised between laboratories, so the same blood can produce different results in different places, and the 2022 American Heart Association statement lists this as an unresolved gap [2] [7]. Laboratories also report in two different units, mg/dL or nmol/L, which counts particles rather than weighing them; every number above is mg/dL.
• Average levels differ by ancestry, lowest in people from east Asia, Europe and southeast Asia and highest in people from Africa, with up to a threefold gap in typical levels between populations [1] [4]. A 2022 review still concluded that the test's predictive value does not vary enough to justify separate thresholds by ancestry [6].

Two findings remain unresolved. Very low Lp(a) may be linked to a higher risk of diabetes, which the European panel flagged as needing study rather than as settled [14]. And Lp(a) is not a general marker of how ill someone is: among 211 patients admitted with COVID-19 before vaccines existed, the level was not associated with the rate of hospital death or discharge [12].

Lp(a) belongs to the advanced lipid tier rather than the standard cholesterol panel, which is why it shows up on the comprehensive biomarker panels that longevity clinics offer, and why many people meet the test there rather than at a routine check-up with their own doctor. A first visit is usually a consultation and a blood draw, and since Lp(a) needs no fasting it can be added to whatever else is being taken that day [4]. What no clinic can offer is a better number next year: the level is stable for life, so an annual repeat buys a reading you already have [1] [10]. The figure on its own does nothing. What it can change is how everything else gets managed, and with no approved Lp(a)-lowering drug available, the European panel's position is early and intensive attention to the other risk factors, scaled to overall risk and to the Lp(a) level [14].